Myriad Genetics/$MYGN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Myriad Genetics
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
- Ticker
- $MYGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,700
- Headquarters
- Salt Lake City, United States
- Website
- www.myriad.com
Myriad Genetics Metrics
BasicAdvanced
$533M
-
-$1.20
1.67
-
Price and volume
Market cap
$533M
Beta
1.67
52-week high
$8.50
52-week low
$2.74
Average daily volume
2.9M
Financial strength
Current ratio
2.211
Quick ratio
1.719
Long term debt to equity
0.669
Total debt to equity
0.693
Interest coverage (TTM)
-5.54%
Profitability
EBITDA (TTM)
-42.2
Gross margin (TTM)
68.83%
Net profit margin (TTM)
-13.96%
Operating margin (TTM)
-11.26%
Effective tax rate (TTM)
-0.72%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-8.59%
Return on equity (TTM)
-32.54%
Valuation
Price to revenue (TTM)
0.647
Price to book
1.75
Price to tangible book (TTM)
4.52
Price to free cash flow (TTM)
-36.754
Free cash flow yield (TTM)
-2.72%
Free cash flow per share (TTM)
-0.152
Growth
Revenue change (TTM)
-3.16%
Earnings per share change (TTM)
-72.17%
3-year revenue growth (CAGR)
4.89%
3-year earnings per share growth (CAGR)
-26.76%
What the Analysts think about Myriad Genetics
Analyst ratings (Buy, Hold, Sell) for Myriad Genetics stock.
Analyst projections of the future price of Myriad Genetics stock.
Bulls say / Bears say
Cancer Care Continuum test volumes grew 6% in Q2, including 10% growth in MyRisk, while Myriad expanded Precise MRD testing and launched Prolaris + AI. This gives its oncology business several avenues to build on existing demand. (Myriad Genetics)
GeneSight test volumes rose 4% in Q2 and the number of ordering clinicians reached a record of more than 40,000. Management says wider coverage and biomarker legislation are supporting the franchise. (Myriad Genetics, Investing.com)
Myriad expects its Ascend efficiency programme to deliver measurable adjusted EBITDA benefits from 2027, while its portfolio review is directing attention towards cancer testing. Successful execution could improve profitability and focus investment on the company’s strategic priority. (Investing.com, Myriad Genetics)
Q2 revenue fell 11% year on year as average revenue per test dropped 9%, amid payer friction and an $11 million adjustment to prior-period collections. Myriad cut its 2026 revenue outlook to $770–790 million and suspended adjusted EBITDA guidance. (Myriad Genetics)
Prenatal Health volumes fell 9% in Q2 and 11% in the first half, while Q2 revenue declined 16%. Continued weakness in this business is offsetting growth in cancer and mental health testing. (Myriad Genetics, Investing.com)
Myriad reported a Q2 operating loss of $38.9 million and a net loss of $43.2 million, alongside $10.9 million of adjusted free-cash outflow. Its $115.2 million cash balance leaves limited room for sustained losses if the turnaround takes longer than expected. (Myriad Genetics)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
Myriad Genetics Financial Performance
Revenues and expenses
Myriad Genetics Earnings Performance
Company profitability
Upcoming events
No upcoming events
Myriad Genetics News
AllArticlesVideos
Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp
Benzinga2 days ago
This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse.
Barrons2 months ago
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Business Wire2 months ago
Funds containing Myriad Genetics
Fund name | Fund size | $MYGN weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.3B | 0.05% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.05% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.